On the other hand, the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial enrolled 614 patients with symptomatic heart failure, LVEF 20–50%, moderate or severe MR, a telediastolic diameter less than 70 mm, and at least one HHF or an BNP in serum increase. The gene discussed is NPPB; the disease is heart failure.